Galmed Pharma Granted Patent In South Korea For Aramchol And Rezdiffra Combination Therapy In NASH/MASH And Liver Fibrosis

The new patent granted in South Korea is added to earlier patents already granted by the United States Patent and Trademark Office (USPTO), Europe, Canada and other jurisdictions and will expire in the U.S. in July 2042.

Aramchol is a first-in-class, Phase 3 ready, drug candidate, that showed robust fibrosis improvement in advanced clinical studies. 

Aramchol's excellent safety and tolerability is a perfect drug candidate to be combined with other MASH drugs, approved or in development.

RAMAT-GAN, Israel, Dec. 4, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced today the grant of a new Use Patent related to its lead compound, Aramchol. The patent covers the use of a combination therapy of Aramchol and Rezdiffra (MGL-3196, resmetirom) for the treatment of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH), and liver fibrosis in South Korea.